search
Back to results

Midazolam Used Alone or Sequential Use of Midazolam and Propofol/Dexmedetomidine in Mechanically Ventilated Patients

Primary Purpose

Mechanical Ventilation, Complication, Delirium

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
midazolam
Fentanyl
propofol
Dexmedetomidine
Procedure:sedation assessment
Procedure:Weaning
midazolam(used for passing the SBT safety screen)
Sponsored by
West China Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mechanical Ventilation focused on measuring sedation, Midazolam, Propofol, Dexmedetomidine

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Intubated patients;
  2. Age≥18 years old;
  3. Anticipated Ventilation and sedation duration of at least 72 hours.

Exclusion Criteria:

  1. Allergy to the study drug;
  2. suspected pregnancy;
  3. gross obesity;
  4. Extremely unstable of circulatory system, such as systolic blood pressure less than 90 mm Hg despite plasma volume expansion and continuous infusions of vasopressors before the start of study drug infusion;
  5. Uncontrolled abnormal hypertension, such as systolic blood pressure more than 180 mmHg or diastolic more than105 mmHg;
  6. Heart rate less than 50 bpm;
  7. Second or third degree heart block;
  8. moribund state;
  9. history of alcoholism or intake of anti-anxiety drugs or hypnotics;
  10. chronic renal failure;
  11. coma by cranial trauma or neurosurgery or unknown etiology or epileptic state;
  12. History of neuromuscular disease;
  13. unwillingness to provide informed consent by patients or their authorized surrogates following ICU admission.

Sites / Locations

  • Department of Critical care medicine of West China Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

midazolam

midazolam/propofol

midazolam/dexmedetomidine

Arm Description

Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation. After the spontaneous breathing trial safety screen is passed, midazolam will continue to be used for sedation, with the dosage adjusted to achieve the desired level of sedation.

Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation. After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.

Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation. After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5 μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to achieve the desired level of sedation.

Outcomes

Primary Outcome Measures

Weaning time

Secondary Outcome Measures

The pharmaceutical costs of sedation
The total ICU costs
The incidence of delirium (patients with diagnosis of delirium/ total patients in each group × 100% )
After the daily interruption of continuous sedation,delirium is assessed by the the confusion assessment method for the diagnosis of delirium in ICU(CAM-ICU). If the patient has the clinical features of 1 and 2, or 3,or 4 in the CAM-ICU, delirium can be diagnosed.
Sedation satisfaction degree (The total time within target sedation level/total evaluation times ×100% )

Full Information

First Posted
August 15, 2015
Last Updated
April 26, 2016
Sponsor
West China Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02528513
Brief Title
Midazolam Used Alone or Sequential Use of Midazolam and Propofol/Dexmedetomidine in Mechanically Ventilated Patients
Official Title
Midazolam Used Alone or Sequential Use of Midazolam and Propofol/Dexmedetomidine for Long-Term Sedation in Critically Ill, Mechanically Ventilated Patients: a Prospective, Randomized Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Unknown status
Study Start Date
December 2015 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
February 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
West China Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study was to evaluate effects, safety and cost of midazolam used alone or sequential use of midazolam and propofol/dexmedetomidine for long-term sedation in critically ill, mechanically ventilated patients.
Detailed Description
It is well known that sedation is frequently required as a component of compassionate care in critically ill patients. Until now, there is no ideal sedation drug and every sedation drug has its advantage and disadvantage for long-term sedation in critically ill, mechanically ventilated patients. The sequential use of midazolam and propofol for long-term sedation was associated with a faster recovery, earlier extubation, shorter mechanical ventilation time and less cost of total ICU treatment compared with midazolam alone, The protocol was associated with less cost of pharmaceutical sedation compared with propofol alone. But, propofol and midazolam may cause respiratory depression and delirium. Both drugs should be stopped after the patient passed the screen of weaning from mechanical ventilation, then it would induce the stress response and agitation, it would cause prolonged sedation and delay extubation. Dexmedetomidine is a centrally acting a2-receptor agonist, has less effect on arousability and respiratory depression. The purpose of this study was to evaluate effects, safety and cost of midazolam used alone or sequential use of midazolam and propofol/dexmedetomidine for long-term sedation in critically ill, mechanically ventilated patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mechanical Ventilation, Complication, Delirium
Keywords
sedation, Midazolam, Propofol, Dexmedetomidine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
midazolam
Arm Type
Experimental
Arm Description
Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation. After the spontaneous breathing trial safety screen is passed, midazolam will continue to be used for sedation, with the dosage adjusted to achieve the desired level of sedation.
Arm Title
midazolam/propofol
Arm Type
Experimental
Arm Description
Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation. After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.
Arm Title
midazolam/dexmedetomidine
Arm Type
Experimental
Arm Description
Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation. After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5 μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to achieve the desired level of sedation.
Intervention Type
Drug
Intervention Name(s)
midazolam
Other Intervention Name(s)
Liyuxi
Intervention Description
Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
Intervention Type
Drug
Intervention Name(s)
Fentanyl
Intervention Description
Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool(CPOT)score(0-1).
Intervention Type
Drug
Intervention Name(s)
propofol
Intervention Description
After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Intervention Description
After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
Intervention Type
Procedure
Intervention Name(s)
Procedure:sedation assessment
Intervention Description
The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
Intervention Type
Procedure
Intervention Name(s)
Procedure:Weaning
Intervention Description
the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
Intervention Type
Drug
Intervention Name(s)
midazolam(used for passing the SBT safety screen)
Other Intervention Name(s)
Liyuxi
Intervention Description
After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
Primary Outcome Measure Information:
Title
Weaning time
Time Frame
From sedation sequential criteria to extubation, up to 28 days
Secondary Outcome Measure Information:
Title
The pharmaceutical costs of sedation
Time Frame
From sedation drug is used to cessation of sedation up to 28 days.
Title
The total ICU costs
Time Frame
From admitted to ICU until ventilation and participants discharged from ICU, up to 28 days.
Title
The incidence of delirium (patients with diagnosis of delirium/ total patients in each group × 100% )
Description
After the daily interruption of continuous sedation,delirium is assessed by the the confusion assessment method for the diagnosis of delirium in ICU(CAM-ICU). If the patient has the clinical features of 1 and 2, or 3,or 4 in the CAM-ICU, delirium can be diagnosed.
Time Frame
From sedation drug is used to cessation of sedation, up to 28 days.
Title
Sedation satisfaction degree (The total time within target sedation level/total evaluation times ×100% )
Time Frame
From sedation drug is used to cessation of sedation up to 28 days.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Intubated patients; Age≥18 years old; Anticipated Ventilation and sedation duration of at least 72 hours. Exclusion Criteria: Allergy to the study drug; suspected pregnancy; gross obesity; Extremely unstable of circulatory system, such as systolic blood pressure less than 90 mm Hg despite plasma volume expansion and continuous infusions of vasopressors before the start of study drug infusion; Uncontrolled abnormal hypertension, such as systolic blood pressure more than 180 mmHg or diastolic more than105 mmHg; Heart rate less than 50 bpm; Second or third degree heart block; moribund state; history of alcoholism or intake of anti-anxiety drugs or hypnotics; chronic renal failure; coma by cranial trauma or neurosurgery or unknown etiology or epileptic state; History of neuromuscular disease; unwillingness to provide informed consent by patients or their authorized surrogates following ICU admission.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Y Kang, Dr
Organizational Affiliation
Critical Medicine Department,West China Hospital of Sichuan University
Official's Role
Study Chair
Facility Information:
Facility Name
Department of Critical care medicine of West China Hospital
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
35505432
Citation
Zhou Y, Yang J, Wang B, Wang P, Wang Z, Yang Y, Liang G, Jing X, Jin X, Zhang Z, Deng Y, Hu C, Liao X, Yin W, Tang Z, Tian Y, Tao L, Kang Y. Sequential use of midazolam and dexmedetomidine for long-term sedation may reduce weaning time in selected critically ill, mechanically ventilated patients: a randomized controlled study. Crit Care. 2022 May 3;26(1):122. doi: 10.1186/s13054-022-03967-5.
Results Reference
derived

Learn more about this trial

Midazolam Used Alone or Sequential Use of Midazolam and Propofol/Dexmedetomidine in Mechanically Ventilated Patients

We'll reach out to this number within 24 hrs